HONG KONG, Nov. 7 An interim analysis of 12-month patientsubset data from e-HEALING, a global post-marketing surveillance registry ofOrbusNeich's Genous Bio-engineered R stent, will be presented next week at theAmerican Heart Association (AHA) Scientific Sessions 2008 in New Orleans.
Sigmund Silber, M.D., F.A.C.C., F.E.S.C., a professor of medicine with theCardiology Practice and Hospital, Munich, will present the data at 9:30 a.m.CST on Nov. 12 in Auditorium C at the Ernest N. Morial Convention Center.Silber and Robbert de Winter, M.D., Ph.D., F.E.S.C., a professor of medicinewith the Academic Medical Center, Amsterdam, are the co-principalinvestigators of e-HEALING.
OrbusNeich's e-HEALING is a multi-center, worldwide (outside the UnitedStates) prospective registry with 5,000 enrolled patients treated with theGenous Bio-engineered R stent. The study protocol recommends that patientsreceive one month of clopidogrel treatment after the procedure. Clinicalfollow-up takes place at 30 days, six months and 12 months. The primaryendpoint of the registry is target vessel failure at 12 months.
Unlike drug-eluting stents, Genous, which is coated with an antibody,captures a patient's endothelial progenitor cells (EPCs) to accelerate thenatural healing process. EPCs circulate in the bloodstream and are involved inthe repair of blood vessels. When attracted to the surface of Genous, EPCsrapidly form an endothelial layer over the stent that provides protectionagainst thrombus and minimizes restenosis.
OrbusNeich designs, develops, manufactures and markets innovative medicaldevices for the treatment of vascular diseases. The company's productportfolio includes the Genous Bio-engineered R stent, an antibody-coateddevice that is the first-ever stent to capture a patient's endothelialprogenitor cells (EPCs) to accelerate the natural healing process followingplacement. Other products are stents, balloons and guiding catheters marketedunder the names of Blazer(TM), R stent(TM), Scoreflex(TM), Sapphire(TM),Sapphire(TM) NC, Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.
A global company, OrbusNeich is headquartered in Hong Kong and hasoperations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; andShenzhen, China. OrbusNeich, which has provided cardiology devices tophysicians through its predecessor companies since 1979, today suppliesproducts to interventional cardiologists in more than 60 countries. For moreinformation, visit www.OrbusNeich.com.